174 related articles for article (PubMed ID: 21838886)
1. Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS.
Asano T; Koizumi S; Takagi A; Hatori T; Kuwabara K; Fujino O; Fukunaga Y
BMC Neurol; 2011 Aug; 11():101. PubMed ID: 21838886
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel biomarker candidates by proteomic analysis of cerebrospinal fluid from patients with moyamoya disease using SELDI-TOF-MS.
Araki Y; Yoshikawa K; Okamoto S; Sumitomo M; Maruwaka M; Wakabayashi T
BMC Neurol; 2010 Nov; 10():112. PubMed ID: 21059247
[TBL] [Abstract][Full Text] [Related]
3. Visualization of different characteristics of cerebrospinal fluid with acute encephalopathy and febrile seizures using pattern recognition analysis of 1H NMR.
Asano T; Hirakawa K; Koike K; Ohno Y; Fujino O
Pediatr Res; 2015 Jan; 77(1-1):70-4. PubMed ID: 25268146
[TBL] [Abstract][Full Text] [Related]
4. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.
Rüetschi U; Zetterberg H; Podust VN; Gottfries J; Li S; Hviid Simonsen A; McGuire J; Karlsson M; Rymo L; Davies H; Minthon L; Blennow K
Exp Neurol; 2005 Dec; 196(2):273-81. PubMed ID: 16154129
[TBL] [Abstract][Full Text] [Related]
5. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
O'Gorman D; Howard JC; Varallo VM; Cadieux P; Bowley E; McLean K; Pak BJ; Gan BS
Clin Invest Med; 2006 Jun; 29(3):136-45. PubMed ID: 17058431
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential CSF biomarkers in ALS.
Pasinetti GM; Ungar LH; Lange DJ; Yemul S; Deng H; Yuan X; Brown RH; Cudkowicz ME; Newhall K; Peskind E; Marcus S; Ho L
Neurology; 2006 Apr; 66(8):1218-22. PubMed ID: 16481598
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.
Ranganathan S; Williams E; Ganchev P; Gopalakrishnan V; Lacomis D; Urbinelli L; Newhall K; Cudkowicz ME; Brown RH; Bowser R
J Neurochem; 2005 Dec; 95(5):1461-71. PubMed ID: 16313519
[TBL] [Abstract][Full Text] [Related]
8. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic indicators of acute encephalopathy in patients with complex febrile seizures.
Nagase H; Nakagawa T; Aoki K; Fujita K; Saji Y; Maruyama A; Uetani Y
Pediatr Int; 2013 Jun; 55(3):310-4. PubMed ID: 23279186
[TBL] [Abstract][Full Text] [Related]
10. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.
Liu XP; Shen J; Li ZF; Yan L; Gu J
Cancer Invest; 2006 Dec; 24(8):747-53. PubMed ID: 17162557
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
[TBL] [Abstract][Full Text] [Related]
13. Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children.
Devarajan P; Krawczeski CD; Nguyen MT; Kathman T; Wang Z; Parikh CR
Am J Kidney Dis; 2010 Oct; 56(4):632-42. PubMed ID: 20599305
[TBL] [Abstract][Full Text] [Related]
14. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
15. SELDI-TOF MS Analysis of Hepatocellular Carcinoma in an Australian Cohort.
Schlichtemeier SM; Nahm CB; Xue A; Gill AJ; Smith RC; Hugh TJ
J Surg Res; 2019 Jun; 238():127-136. PubMed ID: 30771682
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
[TBL] [Abstract][Full Text] [Related]
17. SELDI-TOF-MS of saliva: methodology and pre-treatment effects.
Schipper R; Loof A; de Groot J; Harthoorn L; Dransfield E; van Heerde W
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):45-53. PubMed ID: 17070117
[TBL] [Abstract][Full Text] [Related]
18. Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis.
Wada-Isoe K; Michio K; Imamura K; Nakaso K; Kusumi M; Kowa H; Nakashima K
J Neural Transm (Vienna); 2007; 114(12):1579-83. PubMed ID: 17690946
[TBL] [Abstract][Full Text] [Related]
19. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS).
Hong H; Dragan Y; Epstein J; Teitel C; Chen B; Xie Q; Fang H; Shi L; Perkins R; Tong W
BMC Bioinformatics; 2005 Jul; 6 Suppl 2(Suppl 2):S5. PubMed ID: 16026602
[TBL] [Abstract][Full Text] [Related]
20. Saliva analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) in orthodontic treatment: first pilot study.
Ciavarella D; Mastrovincenzo M; D'Onofrio V; Chimenti C; Parziale V; Barbato E; Lo Muzio L
Prog Orthod; 2011 Nov; 12(2):126-31. PubMed ID: 22074837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
